Convergent TP53 loss and evolvability in cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Mansur, MB
Greaves, M
Greaves, M
Document Type
Journal Article
Date
2023-09-25
Date Accepted
2023-08-10
Abstract
Cancer cell populations evolve by a stepwise process involving natural selection of the fittest variants within a tissue ecosystem context and as modified by therapy. Genomic scrutiny of patient samples reveals an extraordinary diversity of mutational profiles both between patients with similar cancers and within the cancer cell population of individual patients. Does this signify highly divergent evolutionary trajectories or are there repetitive and predictable patterns?Major evolutionary innovations or adaptations in different species are frequently repeated, or convergent, reflecting both common selective pressures and constraints on optimal solutions. We argue this is true of evolving cancer cells, especially with respect to the TP53 gene. Functional loss variants in TP53 are the most common genetic change in cancer. We discuss the likely microenvironmental selective pressures involved and the profound impact this has on cell fitness, evolvability and probability of subsequent drug resistance.
Citation
BMC Ecology and Evolution, 2023, 23 (1), pp. 54 -
Source Title
BMC Ecology and Evolution
Publisher
BMC
ISSN
2730-7182
eISSN
2730-7182
2730-7182
2730-7182
Collections
Research Team
Biol Childhood Leukaemia